This article is more than 5 years old. Information may no longer be current.
AASK: ACE inhibitors most effective for chronic kidney disease
Click Here to Manage Email Alerts
Black patients with hypertensive renal disease assigned to an ACE inhibitor continued a trend towards lower incidence of renal outcomes than those receiving a calcium channel blocker, according to recent data.
The results from the follow-up phase of the NIDDK-sponsored African American Study of Kidney Disease (AASK) were presented by Jackson T. Wright, Jr., MD, PhD, professor of medicine at Case Western Reserve University. The results of the study’s first phase were published in 2002.
Wright and colleagues followed 759 patients from the initial study (n=1,094) who had hypertension for five years.
All patients were initially treated with an ACE inhibitor, calcium channel blocker or beta blocker and were then divided into a low-BP target group (mean arterial pressure <92 mm Hg) and a common-BP target group (mean arterial pressure between 102 mm Hg and 107 mm Hg).
“Across both phases of AASK, favorable trends supporting the use of ACE inhibitors were observed,” Wright said. “There was no significant benefit of the lower BP goal seen in the primary analysis of all patients during the trial or after five years of extended follow-up for the entire cohort, but a possible long-term benefit of initial assignment to the lower BP goal was seen in those with a baseline protein/creatinine ratio of greater than 0.22.” – by Eric Raible
For more information:
- Wright J. Progression of hypertensive kidney disease in AASK and the AASK cohort study. Presented at: American Society of Hypertension 23rd Scientific Meeting; May 14-17; New Orleans.